Login
$ATYR
$5.24 +$0.00 (0.0%) After hours

$ATYR SEC Filings

Filed On Filing
13 Nov 2026 8-K: Other Events
06 Nov 2026 8-K: Other Events

Cooley llp 10265 Science Center Drive San Diego, CA 92121t: (858) 550-6000 f: (858) 550-6420 cooley.com

06 Nov 2026 424B5
06 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated.

04 Nov 2026 SCHEDULE 13G/A
27 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

aTyr Pharma, Inc. (the “Corporation”), a corporation organized and existing under the laws of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows:

16 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,087,425 shares of the ...

07 Oct 2026 SCHEDULE 13G/A
01 Oct 2026 Form 4: Yaras Brandon, Chief Financial Officer

Granted 410,000 Employee Stock Option (right to buy)

01 Oct 2026 Form 3: Yaras Brandon, Chief Financial Officer
24 Sep 2026 8-K: Other Events

On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patien...

11 Sep 2026 DEF 14A
31 Aug 2026 PRE 14A
07 Aug 2026 S-8
07 Aug 2026 10-Q
07 Aug 2026 8-K: Results of Operations and Financial Condition

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

06 Aug 2026 SCHEDULE 13G/A
31 Jul 2026 8-K: Termination of a Material Definitive Agreement

This TERMINATION AGREEMENT (this “Agreement”) is made and entered into as of July 30, 2026 (“Execution Date”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road...

27 Jul 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support